A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

NCT02482298 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Ticagrelor
DRUG: Placebo

Sponsor

AstraZeneca